Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9370192 | 1.00 | MIF (0.33) | MIF | |
| SCHEMBL9370199 | 1.00 | MIF (0.33) | MIF | |
| SCHEMBL9364969 | 1.00 | MIF (0.33) | MIF | |
| SCHEMBL9365409 | 0.99 | MIF (0.33) | MIF | |
| SCHEMBL9828916 | 0.99 | MIF (0.33) | MIF | |
| SCHEMBL14163368 | 0.99 | MIF (0.33) | MIF | |
| SCHEMBL966536 | 0.87 | MIF (0.35) | MIF | |
| SCHEMBL12238538 | 0.87 | MIF (0.35) | MIF | |
| SCHEMBL9365286 | 0.87 | MIF (0.35) | MIF | |
| SCHEMBL916725 | 0.87 | MIF (0.35) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245008-B1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARM CORP (KR) | 2013-02-20 | — | — | EP | disclosed |
| US-8178697-B2 | Method for the preparation of atorvastatin and intermediates used therein | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-01-20 | — | — | US | disclosed |
| EP-2245008-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | Chong Kun Dang Pharmaceutical Corp. (KR) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009093776-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008075165-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF [R-(R*, R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | HMGCR, PCSK9, CETP | MIF 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.